GPS Vaccine Plus Opdivo Shows Promise for Pleural Mesothelioma

A novel, targeted cancer vaccine combined with the immunotherapy drug Opdivo has shown surprising efficacy for mesothelioma patients whose disease no longer responds to standard chemotherapy. In a phase I clinical trial at Memorial Sloan Kettering Cancer Center, the galinpepimut-S vaccine, also known as GPS, has produced an impressive, anti-tumor synergy with Opdivo, based upon early data. GPS targets the WT1 protein, which is expressed in high levels of various cancers but rarely seen in normal adult cells. The protein has been especially resistant to standard chemotherapy. The vaccine works by inducing a powerful T-cell immune response against the WT1 antigen. Apart from a low-grade, temporary reaction at the injection site, the vaccine has shown few side effects. SELLAS Life Sciences Group, a biopharmaceutical company based in Switzerland, developed the vaccine. It has already received orphan drug and fast track designations from the U.S. Food and Drug Administration. “Patients treated with this combination appear to be living longer than expected,” Dr. Angelos Stergiou, president and CEO at SELLAS, told The Mesothelioma Center at “It has been quite impressive.” Find Immunotherapy Clinical Trials Learn how to access mesothelioma clinical trials for immunotherapy. Sign Up Now ...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news

Related Links:

This article is licensed under aCreative Commons Attribution-NonCommercial 3.0 Unported Licence.Bjoern C Froehlich, Robert Popp, Constance A Sobsey, Sahar Ibrahim, Andre M LeBlanc, Yassene Mohammed, Marguerite Buchanan, Adriana Aguilar-Mahecha, Oliver Poetz, Michael X Chen, Alan Spatz, Mark Basik, Gerald Batist, Rene Zahedi, Christoph H. Borchers The PI3-kinase/AKT/mTOR pathway plays a central role in cancer signaling. While p110 α is the catalytic α-subunit of PI3-kinase and a major drug target, PTEN is the main negative regulator of... The content of this RSS Feed (c) The Royal Society of Chemistry
Source: RSC - Analyst latest articles - Category: Chemistry Authors: Source Type: research
Source: BMJ Comments - Category: General Medicine Source Type: forums
The White House announced Monday that visitors will be required to show proof of vaccination and a negative COVID-19 test taken within three days of departure.WebMD Health News
Source: Medscape Infectious Diseases Headlines - Category: Infectious Diseases Tags: Infectious Diseases News Source Type: news
ConclusionsThis systematic review suggests that women with HPV- and p16-positive vaginal cancer have an improved prognosis compared with those with HPV- or p16-negative vaginal cancer. Results for p53 were varied, and no conclusion could be reached. Only 12 studies could be included in the review, of which most were based on small populations. Hence, further and larger studies on the prognostic impact of HPV, p16, and p53 in vaginal cancer are warranted.
Source: Acta Obstetricia et Gynecologica Scandinavica - Category: OBGYN Authors: Tags: SYSTEMATIC REVIEW Source Type: research
A correction to this paper has been published:
Source: European Journal of Clinical Pharmacology - Category: Drugs & Pharmacology Source Type: research
This study aims to detail the characteristics of chemotherapy-related acute kidney injury (CR-AKI) and investigate its effect on patient outcomes.MethodsThis is a multicenter cross-sectional study of cancer patients with CR-AKI screened from hospital-acquired adult AKI patients based on a nationwide AKI survey in China.ResultsOf the 3468 patients with hospital-acquired AKI, 258 cases of CR-AKI were identified. Of the patients, 20.1% (52/258) were ≥ 70 years old. Among the 258 CR-AKI cases, 61 (23.6%) reached AKI stage 3, and 75 (29.1%) reached AKI stage 2. The remaining 122 (47.3%) remained at AKI stage 1. A total of 41...
Source: European Journal of Clinical Pharmacology - Category: Drugs & Pharmacology Source Type: research
This study aimed to investigate safety, tolerability, antibody development, and reduction of low-density lipoprotein choleste rol (LDLc) following four subcutaneous immunizations.MethodsThis phase I, single-blind, randomized, placebo-controlled study was conducted in a total of 72 healthy subjects with a mean fasting LDLc level at baseline of 117.1  mg/dL (range 77–196 mg/dL). Each cohort enrolled 24 subjects to receive three priming immunizations at weeks 0, 4, and 8 and to receive a single booster immunization at week 60 of either AT04A, AT06A, or placebo. In addition to safety (primary objective), the an...
Source: European Journal of Clinical Pharmacology - Category: Drugs & Pharmacology Source Type: research
About half of vaccinated Americans are hesitant to gather with unvaccinated family and friends this holiday season, a new Harris poll suggests - reflecting a growing social divide over vaccination.
Source: the Mail online | Health - Category: Consumer Health News Source Type: news
AbstractAs a very promising immunotherapy, PD-1/PD-L1 blockade has revolutionized the treatment of a variety of tumor types, resulting in significant clinical efficacy and lasting responses. However, these therapies do not work for a large proportion of patients initially, which is called primary resistance. And more frustrating is that most patients eventually develop acquired resistance after an initial response to PD-1/PD-L1 blockade. The mechanisms that lead to primary and acquired resistance to PD-1/PD-L1 inhibition have remained largely unclear. Recently, the gut microbiome has emerged as a potential regulator for PD...
Source: Clinical and Translational Oncology - Category: Cancer & Oncology Source Type: research
The U.S. Food and Drug Administration awarded Fast Track designation recently to the WT1 cancer vaccine, moving it closer to becoming the first approved second-line treatment for malignant pleural mesothelioma. The vaccine, also known as galinpepimut-S, is an immunotherapy agent that targets the WT1 protein, which is expressed in high levels in various cancers, such as mesothelioma, but it’s rarely seen in normal adult cells. The protein is especially resistant to standard chemotherapy agents. The National Cancer Institute in 2009 ranked WT1 as the top target of cancer immunotherapy research. Sellas Life Sciences Gro...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Tags: chemotherapy for mesothelioma immunotherapy for mesothelioma malignant pleural mesothelioma treatment second line mesothelioma treatment sellas life sciences group wt1 vaccine Source Type: news
More News: Asbestosis | Brain | Brain Cancers | Cancer | Cancer & Oncology | Cancer Vaccines | Chemotherapy | Clinical Trials | Environmental Health | Food and Drug Administration (FDA) | Immunotherapy | Learning | Mesothelioma | Myeloma | Neurology | Ovarian Cancer | Ovaries | Rare Diseases | Study | Switzerland Health | Universities & Medical Training | Vaccines